We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • eCFR and Guidances
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Drug Products » The CDER Reorganization: What It Means for Drugmakers - Webinar Recording/Transcript

Other Options

Audio Recording/Transcript - Oct. 18, 2018

$287.00

Audio Recording/Transcript - Oct. 18, 2018

$258.00

Audio Recording/Transcript - Oct. 18, 2018

$244.00

Audio Recording/Transcript - Oct. 18, 2018

$230.00

Audio Recording/Transcript - Oct. 18, 2018

$215.00

The CDER Reorganization: What It Means for Drugmakers - Webinar Recording/Transcript

$287.00
Drug Products

Product Details

The CDER Reorganization: What It Means for Drugmakers — Preparing Now for NDA Impact

Drug, biologics and combination product makers with new drug approvals (NDA) in the pipeline are bracing for fallout from the planned reorganization of CDER, the Center for Drug Evaluation and Research.

Will the new therapeutic focus help or hurt you? And what action should you take now? FDAnews has answers.

Former FDA investigator and ORA director Ricki A. Chase — now a consultant advising big-pharma clients on successful ways to deal with the agency — digs into details of the revamp and suggests how they could affect you. You’ll discover:

  • Why a reorganization? Why now? How the Office of New Drugs is organized now, how it will change, how drugmakers view the changes
  • Day-to-day impact: Specific changes expected to the Office of New Drugs and how they’ll impact what you do every day
  • Is there an upside here? What the FDA says is the goal of restructuring, and opportunities and challenges that could result
  • NDAs: The specific impact on new drug application reviews
  • Drug product quality and compliance: How the restructuring may affect these critical CDER and FDA functions, and others beside
  • And much more

New-drug approval — or denial — can make or break you and your organization. The CDER reorganization is expected to hit NDAs first and worse.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing